Technology areas: Biotechnology & Pharmaceuticals • Semiconductors, Circuits & Optics
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Lineage Cell Therapeutics Inc. operates a patent portfolio in the Semiconductors, Circuits & Optics technology area. There are 2 pending office actions currently associated with this portfolio. These actions are distributed across 2 distinct art units, suggesting that the pending matters fall into different technical categories within the field. The prosecution involves 2 distinct examiners. This distribution shows that the company's current patent applications are being reviewed by multiple individuals across different specialized units.
PINKNEY, DAWAYNE is the busiest examiner for Lineage Cell Therapeutics Inc. This examiner is currently responsible for 1 pending office action. With a total of 2 pending office actions, the workload is divided between the 2 distinct examiners. This means that PINKNEY, DAWAYNE is managing 1 of the company's current pending office actions. This distribution shows that no single examiner is managing more than 1 of the company's current pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §102 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PINKNEY, DAWAYNE | 1 | 80.6% | +18.0% |
| MONTANARI, DAVID A | 1 | 64.8% | +49.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18567163 | METHODS AND COMPOSITIONS FOR TREATING RETINAL DISEASES AND CONDITIONS | PINKNEY, DAWAYNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18567163 | METHODS AND COMPOSITIONS FOR TREATING RETINAL DISEASES AND CONDITIONS | PINKNEY, DAWAYNE | — |
| 18548472 | METHODS OF GENERATING OLIGODENDROCYTE PROGENITOR CELLS AND USE THEREOF | MONTANARI, DAVID A | — |
| Art Unit | Apps |
|---|---|
| 2872 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18567163 | METHODS AND COMPOSITIONS FOR TREATING RETINAL DISEASES AND CONDITIONS | PINKNEY, DAWAYNE | 2872 | §103 | Non-Final OA | — | Pending | Dec 05, 2023 |
| 18548472 | METHODS OF GENERATING OLIGODENDROCYTE PROGENITOR CELLS AND USE THEREOF | MONTANARI, DAVID A | 1632 | §102 | Non-Final OA | — | Pending | Aug 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLineage Cell Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Dawayne Pinkney has the most, with 1 of Lineage Cell Therapeutics Inc.'s pending office actions.
Mostly Semiconductors, Circuits & Optics (USPTO Tech Center 2800), based on where its pending office actions are examined.
